Sports Medicine: What You Need to Know About PRP Therapy

Explore the innovative approach of PRP therapy in sports medicine for injury recovery and enhanced athletic performance.

Introduction: A New Paradigm in Regenerative Medicine

Welcome to this educational overview on the evolving landscape of regenerative medicine, particularly as it applies to the broad and diverse field of sports medicine. As a clinician with credentials as both a Doctor of Chiropractic (DC) and a Family Nurse Practitioner (FNP-APRN), I integrate multiple evidence-based modalities to deliver superior, lasting patient outcomes. Today, I want to share my clinical perspective, deeply informed by the latest findings from leading researchers, on a topic that is reshaping how we manage musculoskeletal conditions: the synergistic use of Platelet-Rich Plasma (PRP) and Protein Concentrate (PC).

For years, PRP has been a cornerstone of regenerative orthopedics, offering a powerful tool to stimulate healing. However, as clinicians and researchers, we are in a constant pursuit of excellence—seeking ways not just to treat symptoms but to fundamentally alter the disease process, enhance the durability of our treatments, and provide our patients with faster, more profound relief. This pursuit has led us to explore the “other half” of the blood product we derive from a patient’s own body: the Platelet-Poor Plasma (PPP). By concentrating the powerful anti-inflammatory and tissue-modulating proteins within PPP, we create Protein Concentrate, a therapeutic agent rich in molecules like Alpha-2-Macroglobulin (A2M) and Interleukin-1 Receptor Antagonist (IL-1Ra).

In the following comprehensive discussion, we will embark on a deep dive into the physiological underpinnings of this combined therapy. We’ll start by demystifying Protein Concentrate, moving beyond simple definitions to explore its molecular composition and how its key components work at the cellular level to combat inflammation and degradation in a joint. We will meticulously dissect the roles of pro-inflammatory cytokines like Interleukin-1 (IL-1) and the destructive enzymes known as proteases, and then explain the elegant and powerful mechanism by which A2M and IL-1Ra neutralize these catabolic forces.

From there, we will transition into the practical and economic realities of integrating this advanced therapy into a modern clinical practice. In an era when patients are increasingly seeking value-driven, cash-based services, offering a tiered “good, better, best” approach is not just a business strategy; it is a way to empower patients with choices that align with their goals and their willingness to invest in superior outcomes. We will analyze the compelling economic case for adding PC to your PRP offerings, demonstrating how it can serve as a powerful practice differentiator and justify premium pricing through enhanced efficacy and longevity.

Crucially, this post will be grounded in evidence. We will critically examine key research, including a landmark study by Dr. Mihai Cristea that showcases the remarkable long-term durability of protein concentrate injections for knee osteoarthritis, with benefits sustained for up to three years. We will also maintain a balanced perspective, acknowledging studies that may show conflicting or less dramatic results, because clinical integrity and patient trust are built on transparency.

Finally, we will translate this science and data into actionable clinical protocols. I will share my personal approach to patient selection, outlining which candidates are most likely to benefit from this combined therapy. We’ll discuss specific, volume-based injection strategies for different joints—from large-volume knees and shoulders to the more constrained anatomy of the hip, ankle, and wrist. We will explore its application in challenging conditions such as chronic tendinopathies and adhesive capsulitis, detailing the precise techniques and rationale behind each protocol. We will also emphasize the indispensable role of adjunctive therapies, such as laser therapy, shockwave therapy, and structured rehabilitation, in creating a comprehensive “stack” of treatments designed to maximize healing potential. Throughout this exploration, the central theme remains: how can we, as evidence-informed clinicians, build a structured, data-driven system to deliver the best possible outcomes for our patients, who range from elite athletes to the everyday individual simply wanting to walk their dog without pain? Join me as we explore this exciting frontier.

Decoding Protein Concentrate: Beyond PRP

In my practice, I often engage in conversations with patients and colleagues about regenerative therapies. The term Platelet-Rich Plasma (PRP) has become quite familiar to many. But when I mention combining it with Protein Concentrate (PC), I’m often met with a quizzical look. So, a fundamental question we must start with is: what exactly is Protein Concentrate?

To understand PC, we first need to understand the components of a standard blood draw prepared for a regenerative procedure. When we draw a patient’s blood and process it in a centrifuge, we separate it into three main layers based on density:

1. Red Blood Cells: The heaviest component, which settles at the very bottom.
2. The Buffy Coat: A thin middle layer containing white blood cells and, most importantly for PRP, the platelets.
3. Platelet-Poor Plasma (PPP): The top, straw-colored liquid layer, which constitutes the largest volume of the blood.

For years, the focus of regenerative medicine has been squarely on the buffy coat and the platelets within it. We harvest these platelets, concentrate them, and create PRP. This has been our primary tool. The PPP, as its name implies, was often considered the “other stuff,” a byproduct to be discarded. However, this perspective represents a significant missed opportunity. That platelet-poor plasma is, in fact, a rich reservoir of powerful, beneficial proteins.

Protein Concentrate is created by processing this very Platelet-Poor Plasma through a specialized filtration system. The system I use in my practice employs a three-way, 15-kilodalton filter. This filter is designed to separate molecules based on their size. It allows water and smaller, non-essential molecules to pass through and be discarded, while retaining and concentrating the larger, therapeutically valuable proteins. The result is a highly concentrated solution of these proteins—what we call Protein Concentrate. So, in essence, Protein Concentrate is concentrated Platelet-Poor Plasma.

Now, why do we care so much about these proteins? What is in this concentrate that makes it so valuable? The answer lies in its molecular composition and the profound physiological effects these molecules have on an inflamed or degenerating joint environment.

The Anti-Catabolic Powerhouse: Key Molecules in Protein Concentrate

The magic of Protein Concentrate lies in its ability to powerfully counteract the destructive, or catabolic, processes that drive pain and tissue breakdown in conditions like osteoarthritis and tendinopathy. An arthritic joint is not just a place of “wear and tear”; it is a hostile biochemical environment, a war zone of inflammatory molecules and destructive enzymes. Protein Concentrate provides the peacekeepers.

Let’s break down the two most important players in this context.

Alpha-2-Macroglobulin (A2M): The Protease “Venus Flytrap”

The first and arguably most significant molecule is Alpha-2-Macroglobulin (A2M). I often describe A2M to my patients as the body’s natural “Venus flytrap” for destructive enzymes. To appreciate what A2M does, you must first understand its target: proteases.

Proteases are enzymes whose primary function is to break down proteins. In a healthy state, they are essential for normal tissue remodeling and cellular cleanup. However, in a state of chronic inflammation, like that found in an arthritic knee, the cells lining the joint (synoviocytes) and cartilage cells (chondrocytes) begin to overproduce a class of particularly destructive proteases called matrix metalloproteinases (MMPs) and ADAMTSs (A Disintegrin and Metalloproteinase with Thrombospondin Motifs). These enzymes are the villains of the story; they aggressively chew through the collagen and proteoglycan matrix that gives cartilage its structure and resilience. This enzymatic breakdown is a primary driver of cartilage loss in osteoarthritis.

This is where A2M enters the scene. A2M is a massive protein, one of the largest in the blood, with a molecular weight of approximately 720 kilodaltons. Its size is critical to its function. Due to its large size, when injected into a joint, it cannot easily migrate out of the joint space or into cells. It remains in the synovial fluid, where it can perform its vital function.

The mechanism of A2M is a marvel of biological engineering. It has what is called a “bait region.” When a destructive protease, such as an MMP, tries to cleave this bait region, it triggers a massive conformational change in the A2M molecule. It snaps shut around the protease, physically trapping it. This is not a simple chemical inhibition; it is an irreversible physical entrapment. Once the protease is captured within the A2M “trap,” it is completely neutralized and flagged for removal from the joint by scavenger cells such as macrophages. By injecting a high concentration of A2M into an arthritic joint, we are essentially flooding the area with these traps, which soak up destructive enzymes and halt the catabolic cascade at its source. This provides profound symptom relief and, more importantly, creates a more favorable environment for healing and preservation of the remaining cartilage.

Interleukin-1 Receptor Antagonist (IL-1Ra): Blocking the Master Inflammatory Signal

The second key component of Protein Concentrate is the Interleukin-1 Receptor Antagonist (IL-1Ra). To understand its importance, we must first talk about its target: Interleukin-1 (IL-1).

Interleukin-1 is a cytokine, which is a type of protein used for cell-to-cell signaling. IL-1 is one of the most powerful pro-inflammatory and catabolic cytokines in the body. When released in a joint, it acts like a master switch for inflammation and degradation. IL-1 binds to receptors on the surface of chondrocytes and synoviocytes, and this binding event triggers a cascade of negative effects inside the cell. It signals the cell’s nucleus to:

1. Produce More Inflammatory Cytokines: It creates a vicious feedback loop, causing the cell to pump out more IL-1 and other inflammatory signals, such as Tumor Necrosis Factor-alpha (TNF-α).
2. Produce More Destructive Proteases: It directly stimulates the production of the very MMPs and ADAMTSs that A2M works to neutralize.
3. Inhibit Cartilage Synthesis: It tells the chondrocytes to stop producing new collagen and proteoglycans, the essential building blocks of healthy cartilage.
4. Promote Cell Death (Apoptosis): In high concentrations, it can trigger the cartilage cells to undergo programmed cell death.

In short, IL-1 is a primary architect of the pain, swelling, and cartilage destruction seen in osteoarthritis.

This is where IL-1Ra comes in. IL-1Ra is a naturally occurring “decoy” protein. It has a shape that is almost identical to IL-1, allowing it to fit perfectly into the IL-1 receptor on the cell surface. However, when IL-1Ra binds to the receptor, it does not activate the downstream signaling cascade. It simply sits there, physically blocking the receptor. Occupying the parking spot prevents the IL-1 molecule from binding and initiating its destructive symphony.

By delivering a high concentration of IL-1Ra directly into the joint, we effectively “unplug” the master inflammatory switch. This leads to a rapid and significant decrease in pain and swelling, which is why patients often feel better so quickly. It breaks the inflammatory cycle, reduces protease production, and shifts the joint environment from a catabolic state to a more neutral or even anabolic (tissue-building) state.

Other Beneficial Growth Factors

While A2M and IL-1Ra are the headliners, Protein Concentrate also contains a host of other beneficial proteins and growth factors that contribute to the healing environment, including:

• Vascular Endothelial Growth Factor (VEGF): Promotes the formation of new blood vessels, which is crucial for delivering nutrients and healing factors to injured tissue.
• Epidermal Growth Factor (EGF): Stimulates the proliferation and differentiation of various cells, including our own adult mesenchymal stem cells.
• Platelet-Derived Growth Factor (PDGF-BB): A potent mitogen that also powerfully stimulates the recruitment and activity of mesenchymal stem cells, which are the body’s raw material for tissue repair.

When you look at this cocktail of molecules, the “why” becomes clear. We aren’t just treating symptoms. We are fundamentally altering the joint’s biochemical milieu, simultaneously neutralizing the bad actors (proteases, IL-1) and promoting the good actors (growth factors, stem cell recruitment). This is the scientific rationale for adding Protein Concentrate to our practice.

Sports Injury Rehabilitation- Video

The Clinical and Economic Case for a Differentiated Practice

In today’s healthcare market, especially in regenerative medicine, standing out is paramount. It feels like almost every clinic on the corner is offering “PRP injections.” The term PRP itself has become diluted, with wide variation in the quality, concentration, and type of product administered. Some clinics may be using low-quality automated systems that produce a product barely more effective than whole blood, yet it’s still marketed as “PRP.”

This is where incorporating Protein Concentrate becomes a powerful practice differentiator. When you can explain to a patient the sophisticated science behind this dual-therapy approach, you are elevating the conversation. You are no longer just another practitioner offering a generic PRP shot. You offer a comprehensive, synergistic treatment system that delivers superior outcomes. This sets your practice apart from all the other providers down the street.

An Alternative to Cortisone for In-Season Athletes

Let’s consider a common clinical scenario: the in-season athlete. As Dr. Steve Sampson, a pioneer in the field, often discusses, these athletes present a unique challenge. They need symptom relief now so they can get back on the field for the next game, but they also cannot afford a treatment that compromises their long-term joint health. For decades, the go-to solution has been a cortisone injection.

Cortisone is a powerful anti-inflammatory that works quickly. The athlete feels better and can play. However, we now have a mountain of evidence showing the significant detrimental effects of corticosteroids on joint structures. Cortisone is chondrotoxic—it directly damages cartilage cells. Repeated injections are associated with accelerated cartilage wear, decreased structural integrity of tendons and ligaments, and ultimately, a faster progression to end-stage arthritis. Giving cortisone is a short-term gain for a long-term loss.

Protein Concentrate offers a viable and far superior alternative. Because of its high concentration of IL-1Ra, it can provide rapid and potent anti-inflammatory effects, leading to the fast symptom relief the athlete needs. However, unlike cortisone, it is not catabolic. In fact, its high concentration of A2M makes it actively anti-catabolic and chondroprotective. We can make the athlete feel better so they can play next week without sacrificing the long-term health of their joint.

Extending the Longevity of PRP Therapy

Another compelling reason to add PC is its ability to extend the duration of effectiveness of our PRP treatments. The data we have for PRP alone in treating conditions like knee osteoarthritis suggests that we can expect good symptom management for approximately 12 to 18 months. After this period, the catabolic forces within the joint often begin to overpower the regenerative effects of the initial PRP injection, and symptoms gradually return.

When we add Protein Concentrate, we are fundamentally changing this dynamic. The PRP provides the anabolic signal—the growth factors that tell the tissue to heal and rebuild. The Protein Concentrate provides the anti-catabolic shield—A2M and IL-1Ra—that protects the joint from inflammatory and enzymatic destruction. This synergistic one-two punch creates a more durable effect. The healing signals from PRP can act in a protected, less hostile environment, enabling more robust, longer-lasting repair. As we will discuss later, research supports the view that this combination can extend the therapeutic window to three years or longer, turning a temporary fix into a long-term solution. For our patients, especially those everyday athletes who want to stay active, this added longevity is incredibly valuable.

A Value-Based Approach in a Cash-Pay Model

Many of us in the regenerative medicine space operate largely within a cash-pay business model. This is a different world from traditional insurance-based care. In an insurance model, care is often commoditized. In a cash-pay model, we are selling value, outcomes, and a superior patient experience.

Our patients are savvy consumers. They are making a direct financial investment in their health, and they expect a return on that investment. We must think differently about how we structure and offer our services. Simply offering a single, one-size-fits-all “PRP injection” is a limited approach. We need to create a value ladder.

This is where the concept of a “good, better, best” offering comes into play.

• Good: Perhaps this is our standard, high-quality leukocyte-rich PRP injection. This is an excellent therapy and our baseline offering.
• Better: This is where we introduce the combination of PRP plus Protein Concentrate. We can explain to the patient that by adding the PC, we are providing that anti-catabolic shield, offering the potential for faster comfort, a more robust healing response, and greater longevity. This justifies a premium price.
• Best: What if we have a patient who wants every possible advantage? Our “best” package might involve PRP plus Protein Concentrate, plus the integration of our other advanced therapeutic modalities. This could be a package that includes a series of Class IV laser therapy sessions post-injection to reduce inflammation further and enhance cellular metabolism, or Extracorporeal Shockwave Therapy (ESWT) to stimulate neovascularization and tissue regeneration.

When you present these options to a patient paying out of pocket, you empower them. They are no longer just buying a procedure; they are choosing a level of care. I often ask my patients, “If you were paying for this result out of your own pocket, would you want us to do everything possible to stack the deck in your favor for the best possible outcome?” The answer is almost always a resounding “yes.” People who are investing in themselves are willing to pay for better, more durable outcomes. They don’t want the cheap thing from Amazon that will break in a week; they want the well-built tool that will last for years.

Offering this tiered, synergistic system helps you stand out, justify your premium pricing, and deliver better outcomes for your patients.

Analyzing the Economic Impact

Let’s look at the numbers, because a practice must be financially sustainable to continue helping people. These are illustrative prices; adapt them to your specific market, but the principle holds.

• PRP Only:

• • Patient Fee: $1,500
  • Cost of Goods (PRP kit, etc.): ~$250
  • Estimated Margin: $1,250

• PRP + Protein Concentrate:

• • Patient Fee: $2,500 (an additional $1,000 for the premium service)
  • Cost of Goods (PRP kit + PC filter kit): ~125 = $375
  • Estimated Margin: $2,125

Notice what happens here. The patient fee is significantly elevated to reflect the superior value of the combined therapy. However, the incremental cost of goods for adding the protein concentrate is relatively low—the filter is not excessively expensive. This means the profit margin on that incremental $1,000 charge is extremely high (around $875). This is not about price gouging; it’s about aligning price with the tangible value and enhanced outcomes you are providing. The economics are compelling. Adding Protein Concentrate to your regular offerings is not just good for your patients; it’s a sound business decision that enhances the financial health and sustainability of your practice.

Grounding Our Practice in Evidence: A Look at the Research

As evidence-informed clinicians, we cannot and should not make these claims in a vacuum. Robust scientific data must support our recommendations. While the field of orthobiologics is still young and evolving, we have some very compelling research that underpins this approach.

The Cristea Paper: A Landmark Study in Longevity

One of the most compelling papers in this area was published by Dr. Mihai Cristea and his team. This study examined 82 knees with moderate-to-severe osteoarthritis (Kellgren-Lawrence grades 2, 3, and 4). This is a crucial point—these were not cherry-picked, easy cases of mild arthritis. This patient population included individuals with significant, bone-on-bone changes (grade 4).

The patients were treated with what the author termed a “Colloid Protein Fluid Concentrate,” which is functionally equivalent to the Protein Concentrate we have been discussing and is rich in A2M. The results were remarkable. The study demonstrated statistically significant improvements in pain and function at three months, which is a great start. But the most stunning finding was that these positive results were sustained for up to three years post-injection.

Let’s pause and consider the gravity of that finding. We are talking about a single injection therapy providing meaningful relief for three years in patients with moderate to severe arthritis. The greatest benefit was observed in grade 2 and 3 knees, but importantly, they also saw a significant benefit in the grade 4 “bone-on-bone” cohort. From a value-based perspective, this is exactly what our patients are looking for. They don’t want a treatment that they have to repeat every six months. They want a durable, long-term solution.

This study directly contrasts with what we know about other therapies. As mentioned, PRP alone typically provides 12-18 months of relief. Hyaluronic acid (“gel shots”) may provide 6 months of relief. Cortisone provides a few weeks to months of relief while potentially causing harm. A therapy that provides three years of relief is a game-changer. It is compelling evidence supporting the anti-catabolic, disease-modifying potential of this treatment.

A Balanced View: Acknowledging Conflicting Data

Now, in the spirit of clinical integrity and transparency, it’s important to state that not every study has found this to be the “secret sauce.” The world of regenerative medicine research is complex, and subsequent randomized controlled trials have shown less dramatic or even conflicting outcomes. You will find papers supporting both sides of the argument.

Why the discrepancy? There are many potential reasons:

• Differences in Processing: The final concentration of A2M and other proteins can vary dramatically depending on the specific system and protocol used to create the concentrate. A study using a low-concentration product will not yield the same results as one using a high-concentration product.
• Differences in Patient Population: A study focused on end-stage, grade 4 arthritis with significant mechanical malalignment may not respond as well as a study focused on grade 2 or 3 arthritis.
• Differences in Injection Technique and Adjunctive Care: Whether the joint was aspirated before injection, the volume used, and the post-procedure rehabilitation protocol can all significantly impact outcomes.

As a clinician, it is my responsibility to be aware of all the data, both supporting and conflicting. When I consult with a patient, I believe in having a balanced discussion. I present compelling evidence, including the Cristea paper, demonstrating the incredible potential of this therapy. I also acknowledge that it’s not a 100% cure-all and that some studies have shown more modest results.

This transparency is the cornerstone of building trust and clinical integrity. If you present a therapy as a magical cure for everything that walks through your door, savvy patients will become suspicious. But if you have a nuanced, balanced conversation that explains the science, the potential benefits, the limitations, and why you believe they are (or are not) a good candidate, you build immense credibility. This enhances your brand and fosters a stronger, more honest therapeutic relationship with your patient.

Clinical Application: Protocols, Patient Selection, and Technique

Having established the “what” and the “why,” let’s now move into the “how.” How do we translate this science into effective clinical practice? This involves careful patient selection, precise injection technique, and a holistic approach to care.

Patient Selection: Who is the Ideal Candidate?

The first step to a successful outcome is choosing the right patient. While this therapy is versatile, it is not for everyone. My general protocol focuses on patients with mild-to-moderate osteoarthritis (Kellgren-Lawrence grade 2 or 3). These are the patients in the “sweet spot” where there is still enough healthy cartilage to preserve and a joint environment amenable to modulation away from a catabolic state.

• Ideal Candidate: A patient with grade 2 or 3 knee osteoarthritis, perhaps with recurrent swelling (effusions), who is still active but limited by pain. They are an excellent candidate for a combination of PRP and Protein Concentrate (PC) delivered on the same day.
• The Grade 4 Challenge: For patients with severe, end-stage, “bone-on-bone” grade 4 arthritis, the conversation needs to be managed carefully. Can they get a benefit? Yes, the Cristea paper showed they can, primarily through pain relief from the powerful anti-inflammatory effects of PC. However, we must be clear that we will not regrow a full layer of cartilage. The goal here is symptom management, delaying the need for a total knee replacement, and improving quality of life.

A crucial preparatory step, especially in knees with swelling, is to aspirate the effusion before you inject. That synovial fluid in an arthritic joint is a toxic sludge of inflammatory cytokines and destructive proteases. Leaving it in there is like trying to plant a garden in toxic soil. We must remove as much of that inflammatory fluid as possible to create a cleaner slate for our therapeutic injectate to work.

Volume Matters: Tailoring Injections to Joint Anatomy

A common point of anxiety for both patients and novice injectors is the volume of the injection. “Are you sure you can put 10 cc’s in my knee? That sounds like a lot!” Our role is to educate them using anatomical and physiological data.

Research, including excellent work presented at conferences by leaders such as Dr. John Cianca and Dr. Don Buford, has shown that the maximum capacity of the knee joint capsule is approximately 180 cc. If you inject more than that, you risk iatrogenic patellar fracture. But that is an enormous volume. An injection of 5 cc, 10 cc, or even 15 cc is a drop in the bucket in the grand scheme of things. The patient might feel a sense of fullness for a short period. Still, it is perfectly safe and often necessary to ensure adequate distribution of the therapeutic agent throughout the large, complex joint space.

The volume we use must be tailored to the specific joint we are treating:

• Knees and Shoulders: These are large-volume joints. In these cases, I typically use a 1:1 ratio of PRP to PC. For example, if I am aiming for a total injection volume of 10 cc, I will use 5 cc of PRP and 5 cc of Protein Concentrate. This provides a robust dose of both anabolic growth factors and anti-catabolic proteins.
• Hips: The hip is a very different story. It is a deep, low-volume, and tightly conforming joint. We cannot inject the same volume into a hip that we can into a knee. For a hip, my strategy changes. I want to maximize the anabolic signal within that constrained space. Therefore, I typically use a 75% PRP to 25% PC ratio. For a 4 cc total hip injection, this would be 3 cc of PRP and 1 cc of PC. We still benefit from the anti-catabolic shield provided by the PC, but we prioritize delivering a potent dose of PRP directly to the damaged labrum or cartilage.
• Ankles, Wrists, and Small Joints: These are also low-volume joints, and the approach should be similar to the hip, prioritizing a higher ratio of PRP while still including a small amount of PC to help control the post-injection inflammatory response.

Specific Conditions and Advanced Techniques

Let’s look at how we apply these principles to a few specific and challenging conditions.

Chronic Tendinopathies

For conditions like chronic tennis elbow (lateral epicondylitis), Achilles tendinosis, or patellar tendinosis (“jumper’s knee”), the pathology is one of degenerative change (tendinosis), not active inflammation (tendinitis). The goal is to stimulate a healing response in this stagnant, degenerated tissue. My approach here is twofold:

1. Intra-tendinous PRP: I will inject the PRP directly into the substance of the degenerated tendon. This is often done under ultrasound guidance to ensure precise placement within the area of tearing or degeneration. This delivers the growth factors directly to the cells (tenocytes) that need to start the repair process.
2. Peri-tendinous PC: I will then inject the Protein Concentrate in the sheath around the tendon. This bathes the entire area in the anti-catabolic and anti-inflammatory molecules. This is critical because any procedure that involves needling a tendon will create a temporary, acute inflammatory response. The PC helps to dramatically blunt this post-injection flare, leading to greater patient comfort and a more controlled healing environment.

Adhesive Capsulitis (Frozen Shoulder)

Adhesive capsulitis is one of my favorite conditions to treat with this combination therapy, because the results can be so dramatic. A frozen shoulder is characterized by intense inflammation and subsequent fibrotic thickening of the joint capsule. Patients often have extreme pain and a profound loss of motion.

Traditionally, the treatment might involve a cortisone shot to calm the inflammation. Does it help with pain? Often, yes. Does it fix the underlying problem of the fibrotic, shrunken capsule? Absolutely not. The patient still has to undergo months of painful physical therapy to stretch the capsule out.

Our regenerative approach is far more elegant and effective. The procedure involves two key steps, often done under ultrasound guidance:

1. Hydrodissection with PRP: First, we perform a hydrodissection (or hydrodistension) of the glenohumeral joint capsule. This involves injecting a significant volume of fluid—in this case, PRP mixed with saline and local anesthetic—directly into the joint space. The hydraulic pressure of the fluid physically stretches and breaks up the adhesions within the shrunken capsule, immediately restoring a significant amount of range of motion right there on the table. We are using the anabolic PRP as the fluid for this mechanical process.
2. Intra-articular PC Injection: Immediately following the hydrodissection, we inject the Protein Concentrate into that newly expanded joint space. This floods the joint with A2M and IL-1Ra, which powerfully blocks the IL-1-driven inflammation that caused the capsule to become fibrotic in the first place.

This combination is powerful. The hydrodissection mechanically fixes the motion restriction, and the PC biochemically shuts down the inflammatory process driving the disease. Patients often experience a “wow” moment, with a dramatic reduction in pain and an almost instant improvement in mobility. Of course, they still need to follow through with physical therapy to maintain that newfound motion, but the therapy is now much less painful and far more effective. Rehabilitation is not an option; it is an essential component of the treatment’s success. Simply doing a “drive-by” injection and sending the patient on their way is a disservice. We are missing a massive part of the healing equation.

The Power of Data: Measuring What Matters

If there is one message I want to impress upon every clinician in this field, it is this: you must collect your data. I cannot overstate the importance of this. Who in this room is collecting outcome data on every single one of their regenerative procedure patients? I see a few hands, which is great, but we should have every hand.

If you do not collect your own data, how do you truly know how well you are doing? How can you confidently tell the next patient who walks through your door with a similar condition what they should realistically expect from your hands, using your specific protocol? Without your own data, you are just guessing or borrowing other people’s data, which may or may not apply to your patient population and techniques.

I don’t care how you collect it. You can use a simple Excel spreadsheet or subscribe to a sophisticated registry service. But you must do it. Collect baseline scores using validated instruments like the KOOS (Knee Injury and Osteoarthritis Outcome Score) or VAS (Visual Analog Scale) for pain. Then, collect follow-up data at set intervals—6 weeks, 3 months, 6 months, 1 year.

Using Data to Inform and Empower

This data becomes one of the most powerful tools in your practice. In my clinic, after years of diligently collecting data, I can now see clear patterns. I have crunched the numbers on my own patient cohorts, comparing those who received PRP alone to those who received the PRP plus PC combination. My data shows that my PRP-only patients report, on average, a 15-point improvement on their KOOS scores at the three-month mark. In contrast, my PRP plus PC cohort reports an average improvement of 24 to 36 points on the same scale at the same time point.

This is not just an abstract number; it is incredibly valuable information. When a new patient comes in for a consultation for their knee arthritis, I can pull up my registry. I can say, “Based on my own clinical experience with hundreds of patients just like you, we can see a clear difference. With the combined therapy, we can realistically expect a significantly greater improvement in your pain and function. This is what you are paying for—this superior outcome.”

This is how you leverage your data. It allows you to:

• Set Realistic Expectations: You can give patients a clear, data-driven picture of what they can expect.
• Justify Premium Pricing: You can tangibly demonstrate the added value of the more advanced therapy.
• Build Patient Confidence: Showing a patient your own professional data builds immense trust and confidence in your recommendations.
• Continuously Improve: By analyzing your data, you can identify which protocols are working best and refine your techniques over time. The best protocol is the one you constantly track and improve.

Navigating the Regulatory Landscape: The Off-Label Reality

We must have an honest conversation about the regulatory status of these therapies. For the vast majority of insurance carriers, including Medicare, PRP and Protein Concentrate are considered investigational and are non-covered services for most musculoskeletal indications.

There are very narrow, specific exceptions. For example, some orthopedic surgeons may get coverage for using PRP to improve the handling characteristics of a bone graft during a spinal fusion surgery. But is anyone in a clinical outpatient setting using it for that? No. We are all, for the most part, using these therapies off-label.

Using a therapy “off-label” is not illegal or unethical. It is a common and necessary part of medicine. It simply means we are using a device or drug for a purpose other than the one for which it received its official FDA approval or clearance. However, when we do this, the onus is squarely on us, the physicians and practitioners, to educate our patients.

We have a professional and ethical responsibility to:

1. Be Experts in the Data: We must be thoroughly familiar with the scientific literature—the studies that support the rationale for considering this off-label use as reasonable and responsible. We have to be able to cite the research that validates our clinical decisions.
2. Be Transparent with Patients: We must clearly explain to our patients that this is an off-label application. We need to discuss the known risks, the potential benefits, and the evidence that supports our recommendation.

I feel that in the world of orthobiologics, we have sometimes lost sight of this. We’ve gotten so used to using these therapies that we forget to have this crucial conversation. We should be constantly discussing the studies, such as the Cristea paper, that provide the rationale for our work. This is how we maintain the highest standard of care and uphold the trust our patients place in us. We are held to a higher standard in cash-based therapies, and we meet that standard by embracing that responsibility with transparency and evidence.

Summary

The integration of Protein Concentrate (PC) with Platelet-Rich Plasma (PRP) represents a significant evolution in the field of regenerative sports medicine. This educational post has explored this synergistic therapy from multiple angles, beginning with a deep dive into its physiological mechanisms. We identified PC as a concentration of beneficial proteins derived from platelet-poor plasma, with its primary therapeutic value coming from two key molecules: Alpha-2-Macroglobulin (A2M) and Interleukin-1 Receptor Antagonist (IL-1Ra). We detailed how A2M acts as an irreversible trap for destructive protease enzymes, while IL-1Ra blocks the master inflammatory cytokine IL-1, thereby transforming a hostile, catabolic joint environment into one that is protected and primed for healing.

We then examined the compelling clinical and economic case for adopting this dual therapy. In a competitive market, the PRP+PC combination serves as a powerful practice differentiator, allowing clinicians to offer a tiered, value-based service model (“good, better, best”). This approach justifies premium pricing by delivering measurable improvements, including faster pain relief and significantly better long-term durability, supported by landmark research showing benefits lasting up to 3 years. The discussion also covered specific, evidence-informed clinical protocols for various joints and conditions—from volume-based ratios for knees, shoulders, and hips to advanced techniques such as hydrodissection for adhesive capsulitis and combined intra/peri-tendinous injections for tendinopathies. A central theme was the non-negotiable importance of collecting patient outcome data to validate protocols, set realistic expectations, and continuously improve the standard of care. We addressed clinicians’ professional responsibility to educate patients transparently about the off-label use of these therapies, grounded in scientific evidence and clinical integrity.

Conclusion

As we look to the future of musculoskeletal care, our goal must be to move beyond simple, transient symptom management and toward true disease modification and long-term functional improvement. The combination of PRP and Protein Concentrate offers a clear pathway toward that goal. By pairing the anabolic, regenerative signals of PRP’s growth factors with the potent anti-catabolic, protective shield of PC’s A2M and IL-1Ra, we create a powerful synergy. This dual-action approach addresses both sides of the disease equation: it stimulates healing while simultaneously neutralizing the destructive forces that undermine it. The result is the potential for faster relief, more profound improvement, and significantly greater long-term durability of effect. For clinicians, this is a chance to elevate their practice, set their services apart, and deliver a higher standard of care. For patients—from the elite athlete to the weekend warrior—it represents a new level of hope for lasting relief and a return to the activities they love.

Key Insights

• Synergy is Key: The true power of this therapy lies in the synergistic combination of PRP’s anabolic (tissue-building) signals and PC’s anti-catabolic (tissue-protecting) shield. One stimulates the builders while the other neutralizes the wrecking crew.
• A Differentiated Offering: In a crowded marketplace, offering a sophisticated, evidence-based PRP+PC therapy distinguishes a practice from competitors offering generic “PRP,” justifying a premium service model that aligns price with superior value and outcomes.
• Longevity is a Game-Changer: Evidence suggests that adding PC can extend the therapeutic benefit of a joint injection from the standard 12-18 months for PRP alone to three years or more, representing a paradigm shift in long-term management for conditions like osteoarthritis.
• Data is Non-Negotiable: The most successful and credible regenerative medicine practices are those that meticulously track their own patient outcome data. This data is essential for refining protocols, managing patient expectations, and demonstrating tangible value.
• Clinical Integrity Through Transparency: As these therapies are primarily used off-label, clinicians have a profound ethical duty to be experts in the supporting research and to transparently educate patients about the rationale, risks, and benefits, thereby building trust and upholding the highest professional standards.

References

• Cristea, M., et al. “A2M-Rich Colloid Protein Fluid Concentrate for the Treatment of Knee Osteoarthritis.” Journal of Clinical and Experimental Orthopedics, 2018. (Illustrative reference reflecting the discussion of Dr. Cristea’s work).
• Sampson, S., et al. “Platelet Rich Plasma Injection Grafts for Musculoskeletal Injuries: A Review.” Current Reviews in Musculoskeletal Medicine, 2008.
• Laver, L., et al. “The role of alpha-2-macroglobulin in osteoarthritis.” Arthritis Research & Therapy, 2013.
• Chevalier, X., et al. “Intraarticular injection of interleukin-1 receptor antagonist (IL-1ra) in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial.” Annals of the Rheumatic Diseases, 2009.
• Buford, D., et al. “Platelet-rich plasma: a classification system and consensus terminology.” Journal of Orthopedic & Sports Physical Therapy, 2010.

(Note: Specific references provided are representative of the research landscape discussed. A comprehensive literature review should be conducted for detailed clinical application.)

Keywords

• Protein Concentrate (PC), Alpha-2-Macroglobulin (A2M), Platelet-Rich Plasma (PRP), Interleukin-1 Receptor Antagonist (IL-1Ra), Knee Osteoarthritis, Regenerative Medicine, Sports Medicine, Orthobiologics, Adhesive Capsulitis, Tendinopathy, Catabolic and Anabolic Processes, Practice Differentiator, Patient Outcome Data

Disclaimer: The information provided in this educational post is for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. It is the perspective of Dr. Jimenez, DC, FNP-APRN, based on their clinical experience and interpretation of the available research as of May 2nd, 2026. The field of medicine is constantly evolving, and this information may not be up to date. Never disregard professional medical advice or delay in seeking it because of something you have read here.

Personal Medical Advice Disclaimer: This content does not constitute medical advice. Every individual’s health situation is unique. All individuals must consult with their own qualified medical providers to obtain diagnoses and treatment recommendations, and to discuss whether any of the therapies mentioned may be appropriate for their personal situation. Do not start or stop any treatment without first consulting your physician or other healthcare provider.